Merck KGaA Aktie

Halozyme wins a Dutch court order blocking Mercks Keytruda SC in eight European markets, strengthening its position in the patent

Der deutsche Aktienmarkt hat gestern, am Dienstag, fester geschlossen: Der DAX gewann 0,8 Prozent auf 25.449 Punkte. Heute, am Mittwoch,

Mercks 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its

In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.

Frankfurt (www.aktiencheck.de) - Merck-Aktienanalyse von XTB:Die Experten von XTB nehmen die Aktie der Merck KGaA (ISIN: DE0006599905, WKN: 659990, Ticker-Symbol:

MRKs $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The

MRKs remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

A private meeting with the drugmakers top doctor points to the next make-or-break moment for shareholders.

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street